pan-Canadian Oncology Drug Review
Stakeholder Feedback on a pCODR Expert Review Committee Initial Recommendation (Provincial Advisory Group [PAG])

Abemaciclib (Verzenio) for Metastatic Breast Cancer

July 5, 2019
3 Feedback on pERC Initial Recommendation

Name of the Drug and Indication(s): Abemaciclib for MBC

Eligible Stakeholder Role in Review
(Submitter and/or Manufacturer, Patient PAG

Organizations Providing Feedback

*The pCODR program may contact this person if comments require clarification. Contact information will not be included in any public posting of this document by pCODR.

3.1 Comments on the Initial Recommendation

a) Please indicate if the eligible stakeholder agrees, agrees in part, or disagrees with the Initial Recommendation:
   ☒ agrees ☐ agrees in part ☐ disagree

   PAG agrees with the Initial Recommendation.

b) Please provide editorial feedback on the Initial Recommendation to aid in clarity. Is the Initial Recommendation or are the components of the recommendation (e.g., clinical and economic evidence) clearly worded? Is the intent clear? Are the reasons clear?

<table>
<thead>
<tr>
<th>Page Number</th>
<th>Section Title</th>
<th>Paragraph, Line Number</th>
<th>Comments and Suggested Changes to Improve Clarity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>The initial recommendation in the endocrine naive/sensitive population makes no reference to previous systemic chemotherapy in both the recommendation and appendix, which is inconsistent with recommendations for palbociclib/ribociclib plus NSAI. However, because the initial recommendation for abemaciclib is for patients who are intolerant of other CDK 4/6 inhibitors, by default eligibility would be limited to patients who had no previous systemic treatment for metastatic breast cancer. PAG noted it would be important to include this clarification.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>For the endocrine naive/sensitive population, add clarification that postmenopausal includes pre or perimenopausal women who would be treated with an LHRH agonist to induce postmenopausal status (either chemically or surgically), this would align with Appendix.</td>
</tr>
</tbody>
</table>
3.2 Comments Related to Eligible Stakeholder Provided Information

Notwithstanding the feedback provided in part a) above, please indicate if the Stakeholder would support this Initial Recommendation proceeding to Final pERC Recommendation ("early conversion"), which would occur two (2) Business Days after the end of the feedback deadline date.

☑ Support conversion to Final Recommendation. Recommendation does not require reconsideration by pERC.

☐ Do not support conversion to Final Recommendation. Recommendation should be reconsidered by pERC.

If the eligible stakeholder does not support conversion to a Final Recommendation, please provide feedback on any issues not adequately addressed in the Initial Recommendation based on any information provided by the Stakeholder in the submission or as additional information during the review.

Please note that new evidence will be not considered at this part of the review process, however, it may be eligible for a Resubmission. If you are unclear as to whether the information you are providing is eligible for a Resubmission, please contact the pCODR program.

Additionally, if the eligible stakeholder supports early conversion to a Final Recommendation; however, the stakeholder has included substantive comments that requires further interpretation of the evidence, the criteria for early conversion will be deemed to have not been met and the Initial Recommendation will be returned to pERC for further deliberation and reconsideration at the next possible pERC meeting.

<table>
<thead>
<tr>
<th>Page Number</th>
<th>Section Title</th>
<th>Paragraph, Line Number</th>
<th>Comments related to Stakeholder Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page 21</td>
<td>Appendix</td>
<td></td>
<td>PAG specifically asked about whether patients who had previously been treated with chemotherapy (but were endocrine naïve/sensitive) would be eligible for abemaciclib, but this was not specifically addressed by pERC. The MONARCH 3 study excluded any patients who previously had chemotherapy for advanced breast cancer.</td>
</tr>
<tr>
<td>Page 22</td>
<td>Appendix</td>
<td></td>
<td>Can pERC also issue a time-limited recommendation for patients already on fulvestrant, given patients have been able to receive compassionate supply fulvestrant?</td>
</tr>
</tbody>
</table>
About Stakeholder Feedback

pCODR invites eligible stakeholders to provide feedback and comments on the Initial Recommendation made by the pCODR Expert Review Committee (pERC). (See www.cadth.ca/pcodr for information regarding review status and feedback deadlines.)

As part of the pCODR review process, pERC makes an Initial Recommendation based on its review of the clinical benefit, patient values, economic evaluation and adoption feasibility for a drug. (See www.cadth.ca/pcodr for a description of the pCODR process.) The Initial Recommendation is then posted for feedback from eligible stakeholders. All eligible stakeholders have 10 (ten) business days within which to provide their feedback on the initial recommendation. It should be noted that the Initial Recommendation may or may not change following a review of the feedback from stakeholders.

pERC welcomes comments and feedback from all eligible stakeholders with the expectation that even the most critical feedback be delivered respectfully and with civility.

A. Application of Early Conversion

The Stakeholder Feedback document poses two key questions:

1. Does the stakeholder agree, agree in part, or disagree with the Initial Recommendation?

   All eligible stakeholders are requested to indicate whether they agree, agree in part or disagrees with the Initial Recommendation, and to provide a rational for their response.

   Please note that if a stakeholder agrees, agrees in part or disagrees with the Initial Recommendation, the stakeholder can still support the recommendation proceeding to a Final Recommendation (i.e. early conversion).

2. Does the stakeholder support the recommendation proceeding to a Final Recommendation (“early conversion”)?

   An efficient review process is one of pCODR’s key guiding principles. If all eligible stakeholders support the Initial Recommendation proceeding to a Final Recommendation and that the criteria for early conversion as set out in the pCODR Procedures are met, the Final Recommendation will be posted on the CADTH website two (2) Business Days after the end of the feedback deadline date. This is called an “early conversion” of an Initial Recommendation to a Final Recommendation.

   For stakeholders who support early conversion, please note that if there are substantive comments on any of the key quadrants of the deliberative framework (e.g., differences in the interpretation of the evidence), the criteria for early conversion will be deemed to have not been met and the Initial Recommendation will be returned to pERC for further deliberation and reconsideration at the next possible pERC meeting. Please note that if any one of the eligible stakeholders does not support the Initial Recommendation proceeding to a Final pERC Recommendation, pERC will review all feedback and comments received at a subsequent pERC meeting and reconsider the Initial Recommendation.

B. Guidance on Scope of Feedback for Early Conversion

Information that is within scope of feedback for early conversion includes the identification of errors in the reporting or a lack of clarity in the information provided in the review documents. Based on the feedback received, pERC will consider revising the recommendation document, as appropriate and to provide clarity.
2 Instructions for Providing Feedback

a) The following stakeholders are eligible to submit Feedback on the Initial Recommendation:
   - The Submitter making the pCODR Submission, or the Manufacturer of the drug under review;
   - Patient groups who have provided input on the drug submission;
   - Registered clinician(s) who have provided input on the drug submission; and
   - The Provincial Advisory Group (PAG)

b) Feedback or comments must be based on the evidence that was considered by pERC in making the Initial Recommendation. No new evidence will be considered at this part of the review process, however, it may be eligible for a Resubmission.

c) The template for providing Stakeholder Feedback on pERC Initial Recommendation can be downloaded from the pCODR section of the CADTH website. (See www.cadth.ca/pcodr for a description of the pCODR process and supporting materials and templates.)

d) At this time, the template must be completed in English. The Stakeholder should complete those sections of the template where they have substantive comments and should not feel obligated to complete every section, if that section does not apply.

e) Feedback on the pERC Initial Recommendation should not exceed three (3) pages in length, using a minimum 11 point font on 8 ½” by 11” paper. If comments submitted exceed three pages, only the first three pages of feedback will be provided to the pERC for their consideration.

f) Feedback should be presented clearly and succinctly in point form, whenever possible. The issue(s) should be clearly stated and specific reference must be made to the section of the recommendation document under discussion (i.e., page number, section title, and paragraph). Opinions from experts and testimonials should not be provided. Comments should be restricted to the content of the Initial Recommendation.

h) The comments must be submitted via a Microsoft Word (not PDF) document to pCODR by the posted deadline date.

i) If you have any questions about the feedback process, please e-mail pcodrsubmissions@cadth.ca
Note: CADTH is committed to providing an open and transparent cancer drug review process and to the need to be accountable for its recommendations to patients and the public. Submitted feedback will be posted on the CADTH website (www.cadth.ca/pcodr). The submitted information in the feedback template will be made fully disclosable.